

# ESMO Preceptorship on Gastric Cancer

## PROGRAMME

**ESMO  
PRECEPTORSHIP**

**SINGAPORE  
4-5 DECEMBER 2024**

**Co-Chairs**

Florian Lordick, Germany

Sun Young Rha, Republic of Korea

# ESMO PRECEPTORSHIP PROGRAMME GASTRIC CANCER

Multidisciplinary management, standards of care, therapeutic targets  
and future perspectives

**Singapore**  
**4-5 December 2024**

---

## CO-CHAIRS

Florian Lordick, Germany  
Sun Young Rha, Republic of Korea

## SPEAKERS

Takuji Gotoda, Japan  
Hanneke van Laarhoven, The Netherlands  
Tony K. H. Lim, Singapore  
Matthew C. H. Ng, Singapore

Joanne Y. Y. Ngeow, Singapore  
Elizabeth Smyth, United Kingdom  
Jimmy B. Y. So, Singapore  
Wei Peng Yong, Singapore

---

## LEARNING OBJECTIVES

- To learn the fundamental of epidemiology, aetiology, pathogenesis, molecular events, and ethnic patterns as contributing factors to heterogeneity in gastric cancer (GC)
- To understand the importance of pathology and molecular factors
- To learn about best clinical practice in the multidisciplinary management of gastric and gastro-esophageal junction (GEJ) and esophageal squamous cell cancers in the adjuvant and metastatic settings
- To learn about current best practice for endoscopic and surgical resection of localised gastric cancer
- To be able to compare the benefits of neo-adjuvant, adjuvant approaches and the value of radiotherapy in the management of localised gastro-esophageal cancers
- To learn about the management of patients after progression, in special situations, and side effects of treatments
- To learn about the advances in the treatment and novel targets in gastric cancer

---

## ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](https://www.esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an independent educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano, Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Wednesday, 4 December 2024

09:30-09:40 10'	Welcome and introduction	Florian Lordick, DE Sun Young Rha, KR
09:40-11:10 90'	<b>SESSION 1</b> Epidemiology, pathology and classification of gastric cancer	Chair: Sun Young Rha, KR
25'	Epidemiology, pathogenesis and staging	Florian Lordick, DE
25'	Pathology of gastric and EGJ cancer: Classification and biomarkers	Tony K. H. Lim, SG
25'	A practical approach to hereditary gastric cancers	Joanne Y. Y. Ngeow, SG
15'	Q&A	All
11:10-11:40	Coffee break	
11:40-12:45 65'	<b>SESSION 2</b> Treatment of early and localised gastric cancer	Chair: Florian Lordick, DE
25'	Endoscopic treatment: EMR and ESD	Takuji Gotoda, JP
25'	Surgical approach	Jimmy B. Y. So, SG
15'	Q&A	All
12:45-13:45	Lunch	
13:45-15:15 90'	<b>SESSION 3</b> Perioperative strategy of localised gastric cancer	Chair: Elizabeth Smyth, UK
25'	Adjuvant treatment of gastric cancer	Sun Young Rha, KR
25'	Neo-adjuvant and perioperative concepts	Matthew C. H. Ng, SG
25'	Integration of immune-therapy and targeted therapy	Elizabeth Smyth, UK
15'	Q&A	All
15:15-15:45	Coffee break	
15:45-16:45 60'	<b>SESSION 4</b> Specific situation of metastatic gastric cancer	Chair: Sun Young Rha, KR
25'	Approaches to treatment of oligometastatic disease	Hanneke van Laarhoven, NL
25'	Conversion surgery	Jimmy B. Y. So, SG
10'	Q&A	All
16:45-17:15 30'	<b>SESSION 5</b> Participants clinical case discussion	Chair: Matthew C. H. Ng, SG
30'	Participants clinical case discussion (2x15') ( <i>locally advanced disease</i> )	Faculty
19:00	Networking dinner	

## Thursday, 5 December 2024

09:00-10:30 90'	<b>SESSION 6</b> Systemic treatment of metastatic gastric cancer	<b>Chair:</b> Wei Peing Yong, SG
25'	Standard chemotherapy and sequencing	Florian Lordick, DE
25'	Immunotherapy	Sun Young Rha, KR
25'	Targeted therapy	Wei Peng Yong, SG
15'	Q&A	Faculty
10:30-11:00	Coffee break	
11:00-12:15 75'	<b>SESSION 7</b> Participants clinical case discussion	<b>Chair:</b> Hanneke van Laarhoven, NL
75'	Participants clinical case discussion (5x15') ( <i>advanced disease</i> )	Faculty
12:15-12:20 5'	Conclusion and farewell	Florian Lordick, DE Sun Young Rha, KR
12:20-13:20	Lunch	

**Note:** Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion